{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:14:57Z","timestamp":1791245697755,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.coviro.2011.10.015","type":"journal-article","created":{"date-parts":[[2011,11,11]],"date-time":"2011-11-11T21:05:04Z","timestamp":1321045504000},"page":"548-554","source":"Crossref","is-referenced-by-count":41,"title":["Progress in the development of new therapies for herpesvirus infections"],"prefix":"10.1016","volume":"1","author":[{"given":"Nathan B","family":"Price","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark N","family":"Prichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2011.10.015_bib0005","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1073\/pnas.140123497","article-title":"Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy","volume":"97","author":"Emery","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2011.10.015_bib0010","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/590934","article-title":"Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients","volume":"47","author":"Torres-Madriz","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2011.10.015_bib0015_1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.coviro.2011.10.015_bib0020","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.idc.2010.07.001","article-title":"Antiviral drug resistance: mechanisms and clinical implications","volume":"24","author":"Strasfeld","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.coviro.2011.10.015_bib0025","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","article-title":"Antiviral drugs for cytomegalovirus diseases","volume":"71","author":"Biron","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2011.10.015_bib0030_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/187152609787847758","article-title":"Drug targets in cytomegalovirus infection","volume":"9","author":"Andrei","year":"2009","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.coviro.2011.10.015_bib0035","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","article-title":"Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management","volume":"55","author":"Piret","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9343(82)90055-9","article-title":"Mechanism of action and selectivity of acyclovir","volume":"73","author":"Elion","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.coviro.2011.10.015_bib0045","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1021\/jm000210m","article-title":"Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain","volume":"43","author":"McGuigan","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2011.10.015_bib0050","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/jac\/dkm376","article-title":"Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus","volume":"60","author":"McGuigan","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0055","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/mol.61.2.249","article-title":"Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase","volume":"61","author":"Sienaert","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.coviro.2011.10.015_bib0060_1","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1128\/AAC.01446-10","article-title":"Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers","volume":"55","author":"Pentikis","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0065_1","series-title":"Helicase\u2013Primase Inhibitors: A New Approach to Combat Herpes Simplex Virus and Varicella Zoster Virus","year":"2011"},{"key":"10.1016\/j.coviro.2011.10.015_bib0070","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0402-392","article-title":"New helicase\u2013primase inhibitors as drug candidates for the treatment of herpes simplex disease","volume":"8","author":"Kleymann","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2011.10.015_bib0075","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1517\/13543784.14.2.135","article-title":"Agents and strategies in development for improved management of herpes simplex virus infection and disease","volume":"14","author":"Kleymann","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.coviro.2011.10.015_bib0080","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1099\/vir.0.011221-0","article-title":"A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure","volume":"90","author":"Biswas","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2011.10.015_bib0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/095632020701800102","article-title":"High frequency of spontaneous helicase\u2013primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1","volume":"18","author":"Biswas","year":"2007","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0090","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.antiviral.2010.04.008","article-title":"Effects of therapy using a helicase\u2013primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant","volume":"87","author":"Sukla","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2011.10.015_bib0095","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.drup.2010.11.002","article-title":"Antiviral drug resistance and helicase\u2013primase inhibitors of herpes simplex virus","volume":"14","author":"Field","year":"2011","journal-title":"Drug Resist Update"},{"key":"10.1016\/j.coviro.2011.10.015_bib0100","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1128\/AAC.39.8.1802","article-title":"Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses","volume":"39","author":"Lowe","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0105","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1080\/15257770008045444","article-title":"Guanosine analogues as anti-herpesvirus agents","volume":"19","author":"De Clercq","year":"2000","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.coviro.2011.10.015_bib0110","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/BF02116525","article-title":"Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus","volume":"14","author":"Andrei","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.coviro.2011.10.015_bib0115","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/AAC.45.6.1629-1636.2001","article-title":"Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine","volume":"45","author":"Ng","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/095632029600700301","article-title":"Cidofovir, a new agent with potent anti-herpesvirus activity","volume":"7","author":"Hitchcock","year":"1996","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0125_1","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2011.10.015_bib0130","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1128\/AAC.49.9.3724-3733.2005","article-title":"Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro","volume":"49","author":"Williams-Aziz","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0135","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1128\/AAC.00571-11","article-title":"Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase","volume":"55","author":"James","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0140","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1086\/421912","article-title":"Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection","volume":"190","author":"Bidanset","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2011.10.015_bib0145","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1128\/AAC.48.9.3516-3522.2004","article-title":"Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir","volume":"48","author":"Kern","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/AAC.00971-10","article-title":"Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection","volume":"55","author":"Bravo","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0155","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1086\/656717","article-title":"Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies","volume":"202","author":"Quenelle","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2011.10.015_bib0160","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1128\/AAC.00545-11","article-title":"CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections","volume":"55","author":"Prichard","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0165","first-page":"1","article-title":"CMX001","volume":"33","author":"Painter","year":"2008","journal-title":"Drugs of the Future"},{"key":"10.1016\/j.coviro.2011.10.015_bib0170","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0166-3542(03)00110-4","article-title":"Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney","volume":"59","author":"Ciesla","year":"2003","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2011.10.015_bib0175","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1128\/AAC.47.7.2186-2192.2003","article-title":"In vitro activities of benzimidazole d- and l-ribonucleosides against herpesviruses","volume":"47","author":"Williams","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0180","series-title":"Maribavir: A Promising New Antiherpes Therapeutic Agent","author":"Biron","year":"2006"},{"key":"10.1016\/j.coviro.2011.10.015_bib0185","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1128\/AAC.48.5.1749-1755.2004","article-title":"Activities of benzimidazole d- and l-ribonucleosides in animal models of cytomegalovirus infections","volume":"48","author":"Kern","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0190_1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.coviro.2011.10.015_bib0195","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/rmv.574","article-title":"Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir","volume":"18","author":"Chou","year":"2008","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.coviro.2011.10.015_bib0200","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/AAC.00577-06","article-title":"Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0205","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/AAC.01177-08","article-title":"Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir","volume":"53","author":"Chou","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0210","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1128\/JVI.78.2.710-715.2004","article-title":"Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides","volume":"78","author":"Komazin","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.10.015_bib0215_1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.chom.2011.01.006","article-title":"Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest","volume":"9","author":"Reitsma","year":"2011","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2011.10.015_bib0220","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.1152095","article-title":"Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function","volume":"320","author":"Hume","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.coviro.2011.10.015_bib0225","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1128\/JVI.02174-07","article-title":"Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes","volume":"82","author":"Prichard","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.10.015_bib0230","doi-asserted-by":"crossref","first-page":"e1000275","DOI":"10.1371\/journal.ppat.1000275","article-title":"Viral mimicry of Cdc2\/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress","volume":"5","author":"Hamirally","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2011.10.015_bib0235","doi-asserted-by":"crossref","first-page":"33357","DOI":"10.1074\/jbc.M502672200","article-title":"Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina","volume":"280","author":"Marschall","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2011.10.015_bib0240","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2011.10.015_bib0245","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1021\/jm030316s","article-title":"Synthesis antiviral activity of (Z)- and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides","volume":"47","author":"Zhou","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2011.10.015_bib0250","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1128\/AAC.49.3.1039-1045.2005","article-title":"In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication","volume":"49","author":"Kern","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0255","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1128\/AAC.48.12.4745-4753.2004","article-title":"Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections","volume":"48","author":"Kern","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0260","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1128\/AAC.00468-10","article-title":"Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir","volume":"54","author":"Gentry","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0265","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bcp.2010.09.005","article-title":"Phosphorylation of antiviral and endogenous nucleotides to di- and triphosphates by guanosine monophosphate kinase","volume":"81","author":"Gentry","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coviro.2011.10.015_bib0270","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/AAC.01259-10","article-title":"Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility","volume":"55","author":"Chou","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0275","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.antiviral.2011.08.019","article-title":"Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection","volume":"92","author":"Hakki","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2011.10.015_bib0280","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0285","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/rmv.344","article-title":"Human cytomegalovirus terminase as a target for antiviral chemotherapy","volume":"12","author":"Bogner","year":"2002","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.coviro.2011.10.015_bib0290","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/JVI.72.6.4721-4728.1998","article-title":"Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56","volume":"72","author":"Krosky","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.10.015_bib0295","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jac\/48.6.757","article-title":"Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action","volume":"48","author":"Reefschlaeger","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coviro.2011.10.015_bib0300","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.10.015_bib0305","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","article-title":"First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246","volume":"11","author":"Kaul","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.coviro.2011.10.015_bib0310","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.antiviral.2009.10.007","article-title":"Current status and challenges of antiretroviral research and therapy","volume":"85","author":"Este","year":"2010","journal-title":"Antiviral Res"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625711001349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625711001349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T11:49:49Z","timestamp":1593258589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625711001349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1879625711001349"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2011.10.015","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}